Navigation Links
InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
Date:5/19/2008

EDT on May 20.

Interested investors and others may participate in the InterMune conference call by dialing 888-799-0528 (U.S.) or 706-634-0154 (international), conference ID# 48122233. A replay of the webcast and teleconference will be available approximately three hours after the call.

The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 48122233.

To access a live audio webcast of the conference call, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securit
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. InterMune Announces Progress on Pirfenidone in IPF
2. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Announces Start of Phase 1b Trial of ITMN-191
5. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
6. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
7. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
8. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
9. GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)
10. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
11. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)... , UT Southwestern to Identify and Validate Nov...aling with Innovative Gene Expression Platform , ... -- WaferGen Biosystems, Inc. (OTC Bulletin Board:...ne expression, genotyping, cell biology and stem c...of a research collaboration with the University o...
(Date:1/8/2009)... , Patients treated at the initial dose in an o...ian viral load decline after three days , , Con..., Jan. 8 Anadys Pharmace...sults from the first cohort of an ongoing Phase Ib...tional non-nucleoside polymerase inhibitor. ANA59...
(Date:1/7/2009)... , Late Preterm Infants Drive the Increase , ...re/ -- New government statistics confirm that the ...th rate continues, putting more infants than ever ...g to the March of Dimes. , , Nearly 543,000 bab...ational Center for Health Statistics, which today ...
(Date:1/7/2009)... , BEIJING, Jan. 7 Tiantan Puhu...spuhua.com ), the worldwide leader in using stem c...announced today six new globally experienced addit...icantly expand the hospital,s treatment capabiliti...atients. The six senior doctors include the distin...
Breaking Medicine Technology:WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System 2WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System 3WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System 4WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System 5ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 2ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 3ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 4ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 5ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 6Preterm Births Rise 36 Percent Since Early 1980s 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 3Virtual Radiologic Corporation Announces Pricing of Initial Public Offering 6382 1Virtual Radiologic Corporation Announces Pricing of Initial Public Offering 6382 2Pure Plastics Pitch Proves Perfect 1815 1Pure Plastics Pitch Proves Perfect 1815 2Pure Plastics Pitch Proves Perfect 1815 3BIO key Reports Third Quarter 2007 Results 1228 1BIO key Reports Third Quarter 2007 Results 1228 2BIO key Reports Third Quarter 2007 Results 1228 3BIO key Reports Third Quarter 2007 Results 1228 4BIO key Reports Third Quarter 2007 Results 1228 5Gene in male fish lures females into sex 1225 1
...PRNewswire-FirstCall/ --,Replidyne, Inc. today ann...REP8839, a novel topical antibiotic that has shown...gens including,methicillin-resistant S. aureus (MR...opically applied REP8839 appears safe,well-tolera...drug,absorption into the bloodstream, which is des...
...dates progress and upcoming,milestones on its insu...FirstCall/ - SemBioSys,Genetics Inc. , a biotechno... proteins for metabolic and cardiovascular disease...ting the,development of plant-derived recombinant ...at the 67th Scientific Sessions of the,American Di...
Other Medicine Technology:Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 2Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 3Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 4SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 2SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 3SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 4
(Date:1/8/2009)...009 Continues Growth Trend , , NORTH HOLLYWOOD,...Hospitalist Company, Inc. (Nasdaq: IPCM ), a lea... company, announced today that it has acquired the...tants, Inc. (MACC) in St. Louis, Missouri. The acq... Louis market, where IPC has established a signifi...
(Date:1/8/2009)...SNewswire/ -- The Pew Charitable Trusts announced ...chemical and food safety programs, in its Health &... formerly deputy staff director and general counse...c Works, brings nearly 25 years of experience in e... , , "We are excited to be joined by such an ex...
(Date:1/8/2009)...FirstCall/ -- Cephalon, Inc . (Nasdaq: CEPH ) t...irman and CEO will present at the J.P. Morgan Hea... in San Francisco, CA at approximately 4:00 p.m. P...n will be webcast live on the investor relations s...st will be archived for one week following the bro...
(Date:1/8/2009)...ire-FirstCall/ -- Heska Corporation (Nasdaq: HSK... What: Heska Corporation Invites You to Join I... Earnings Conference Call on the Web, When: ... Where: www.heska.com (click on the Q4 and Yea...e front page of this website)., How: Li...
Breaking Medicine News(10 mins):Health News:IPC The Hospitalist Company Acquires Missouri Practice Group 2Health News:Veteran Environmental Health Expert Erik D. Olson to Join Pew 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 3Health News:Webcast Alert: Heska Announces Fourth Quarter and Year-End 2008 Earnings Conference Call Webcast 2
...xercise may help decrease the risk of breast cance...ore than 74,000 women who were between ages 50 and...o their level of physical activity, which was base...sed. The level of activity the women had at ages 1...
...hat occur during adolescence may mean teenagers sm...han those who take up the habit as adults, suggest...ed that the earlier someone starts smoking, the mo...kers and the more trouble they have in kicking the...
...Association recommends doctors now examine stroke ...hough they may not be showing symptoms. //A new st...trokes have undetected heart disease. Heart diseas...r disease where blood flow to the heart or brain i...
...besity may increase the risk of certain types of c...he National Institutes of Health, reveals obesity ...th adenocarcinoma than with squamous cell carcinom...adenocarcinoma, 139 with squamous cell carcinoma, ...
Other Medicine News:
Inquire
Built-in convexity means added security and skin protection for recessed, retracted and flush stomas...pre-cut openings. Security and confidence achieved by the internal No-Flowback Valves and soft d
Inquire
Superior comfort and flexibility are achieved through the revolutionary air pocket technology in the dimpled, ultra-thin SoftFlex skin barrier along with a discreet pouch shape and size.
Medicine Products: